PYPD | PolyPid Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.30 - 3.41
52 Week Range	2.9500 - 9.20
Beta	2.33
Implied Volatility	529.99%
IV Rank	85.23%
Day's Volume	4,116
Average Volume	6,575
Shares Outstanding	6,803,480
Market Cap	23,027,058
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-06-26

Valuation
Profitability
Growth
Health
P/E Ratio	-0.47
Forward P/E Ratio	N/A
EPS	-7.22
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	59
Country	Israel
Website	PYPD

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

PYPD's peers: ANIX, CUE, INAB, INMB, EFTR, LABP, APGN, NAVB, ANGN, ANEB, ARMP, VRPX, VACC, VRAX, BWV, REVB, HILS, KPRX, PYXS, ZURA, CYTO, ELEV

*Chart delayed

Analyzing fundamentals for PYPD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see PYPD Fundamentals page.

Watching at PYPD technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PYPD Technicals page.